1. Cantley MD, Rainsford KD, Haynes DR (2013) Effects of Osteochondrin S and select connective tissue ribonucleinate components on human osteoclasts in vitro. J Pharm Pharmacol 65(8):1214–1222
2. Lodemann E, Hochheimer G, Pilgramm M (1989) Biologische Wirkungen eines Ribonucleinsäurehaltigen Arzneimittels. Erfahrungsheilkunde. 8:490–494
3. Rainsford KD (1996) Mode of Action, uses and side effects of anti-inflammatory drugs. In: Advances in Anti-Rheumatic Therapy: CRC Press
4. Rainsford K, Bolten W, Schühlein K-H, Dempsey A, Schnitker J (2004) Effects of intramuscular sodium ribonucleinate (Osteochondrin® S) in osteoarthritis of the knee: identification of Responders and Non-Responders. Ann Rheum Dis 63(Suppl. 1):Abst FRI0–406
5. Rainsford K, Jonas A, Ying C, Smith F (2008) Ribonucleate sodium [Osteochondrin® S] inhibits cytokine-induced cartilage-bone degradation but not proteoglycan synthesis. Inflammopharmacology 16(321) Abstract No. P17